BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 30602435)

  • 1. Breast Cancer Resistance Protein and Multidrug Resistance Protein 2 Determine the Disposition of Esculetin-7-O-Glucuronide and 4-Methylesculetin-7-O-Glucuronide.
    Li Y; Song W; Ou X; Luo G; Xie Y; Sun R; Wang Y; Qi X; Hu M; Liu Z; Zhu L
    Drug Metab Dispos; 2019 Mar; 47(3):203-214. PubMed ID: 30602435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast Cancer Resistance Protein and Multidrug Resistance Protein 2 Mediate the Disposition of Leonurine-10-O-β-glucuronide.
    Li X; Xie Y; Qu W; Ou X; Ou X; Wang C; Qi X; Wang Y; Liu Z; Zhu L
    Curr Drug Metab; 2020; 21(13):1060-1067. PubMed ID: 33198612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical inhibition and stable knock-down of efflux transporters leads to reduced glucuronidation of wushanicaritin in UGT1A1-overexpressing HeLa cells: the role of breast cancer resistance protein (BCRP) and multidrug resistance-associated proteins (MRPs) in the excretion of glucuronides.
    Qin Z; Li S; Yao Z; Hong X; Wu B; Krausz KW; Gonzalez FJ; Gao H; Yao X
    Food Funct; 2018 Mar; 9(3):1410-1423. PubMed ID: 29318243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of the efflux transport of demethoxycurcumin-O-glucuronides in HeLa cells stably transfected with UDP-glucuronosyltransferase 1A1.
    Zhang B; Yang J; Qin Z; Li S; Xu J; Yao Z; Zhang X; Gonzalez FJ; Yao X
    PLoS One; 2019; 14(5):e0217695. PubMed ID: 31150474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efflux excretion of bisdemethoxycurcumin-O-glucuronide in UGT1A1-overexpressing HeLa cells: Identification of breast cancer resistance protein (BCRP) and multidrug resistance-associated proteins 1 (MRP1) as the glucuronide transporters.
    Yang J; Zhang B; Qin Z; Li S; Xu J; Yao Z; Zhang X; Gonzalez FJ; Yao X
    Biofactors; 2018 Nov; 44(6):558-569. PubMed ID: 30334318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer resistance protein (ABCG2) determines distribution of genistein phase II metabolites: reevaluation of the roles of ABCG2 in the disposition of genistein.
    Yang Z; Zhu W; Gao S; Yin T; Jiang W; Hu M
    Drug Metab Dispos; 2012 Oct; 40(10):1883-93. PubMed ID: 22736306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curcumin Affects Phase II Disposition of Resveratrol Through Inhibiting Efflux Transporters MRP2 and BCRP.
    Ge S; Yin T; Xu B; Gao S; Hu M
    Pharm Res; 2016 Mar; 33(3):590-602. PubMed ID: 26502886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
    Dahan A; Amidon GL
    Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast Cancer Resistance Protein and Multidrug Resistance Protein 2 Regulate the Disposition of Acacetin Glucuronides.
    Jiang H; Yu J; Zheng H; Chen J; Wu J; Qi X; Wang Y; Wang X; Hu M; Zhu L; Liu Z
    Pharm Res; 2017 Jul; 34(7):1402-1415. PubMed ID: 28421306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coupling of UDP-glucuronosyltransferases and multidrug resistance-associated proteins is responsible for the intestinal disposition and poor bioavailability of emodin.
    Liu W; Feng Q; Li Y; Ye L; Hu M; Liu Z
    Toxicol Appl Pharmacol; 2012 Dec; 265(3):316-24. PubMed ID: 22982073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of efflux transporters on the transport of highly toxic aconitine, mesaconitine, hypaconitine, and their hydrolysates, as determined in cultured Caco-2 and transfected MDCKII cells.
    Ye L; Yang X; Yang Z; Gao S; Yin T; Liu W; Wang F; Hu M; Liu Z
    Toxicol Lett; 2013 Feb; 216(2-3):86-99. PubMed ID: 23200901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polarized macrophage subsets differentially express the drug efflux transporters MRP1 and BCRP, resulting in altered HIV production.
    He H; Buckley M; Britton B; Mu Y; Warner K; Kumar S; Cory TJ
    Antivir Chem Chemother; 2018; 26():2040206617745168. PubMed ID: 29343083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disposition of naringenin via glucuronidation pathway is affected by compensating efflux transporters of hydrophilic glucuronides.
    Xu H; Kulkarni KH; Singh R; Yang Z; Wang SW; Tam VH; Hu M
    Mol Pharm; 2009; 6(6):1703-15. PubMed ID: 19736994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The roles of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated proteins (MRPs/ABCCs) in the excretion of cycloicaritin-3-O-glucoronide in UGT1A1-overexpressing HeLa cells.
    Li S; Xu J; Yao Z; Hu L; Qin Z; Gao H; Krausz KW; Gonzalez FJ; Yao X
    Chem Biol Interact; 2018 Dec; 296():45-56. PubMed ID: 30237061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sulfonation of raloxifene in HEK293 cells overexpressing SULT1A3: Involvement of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in excretion of sulfate metabolites.
    Zhou X; Wang S; Sun H; Wu B
    Drug Metab Pharmacokinet; 2015 Dec; 30(6):425-33. PubMed ID: 26611713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the role of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in the urinary excretion of sulfate and glucuronide metabolites of edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one).
    Mizuno N; Takahashi T; Kusuhara H; Schuetz JD; Niwa T; Sugiyama Y
    Drug Metab Dispos; 2007 Nov; 35(11):2045-52. PubMed ID: 17682070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of intestinal absorption of amtolmetin guacyl in rats: breast cancer resistant protein as a primary barrier of oral bioavailability.
    Rong Z; Xu Y; Zhang C; Xiang D; Li X; Liu D
    Life Sci; 2013 Feb; 92(3):245-51. PubMed ID: 23333829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glyceollin Effects on MRP2 and BCRP in Caco-2 Cells, and Implications for Metabolic and Transport Interactions.
    Chimezie C; Ewing A; Schexnayder C; Bratton M; Glotser E; Skripnikova E; Sá P; Boué S; Stratford RE
    J Pharm Sci; 2016 Feb; 105(2):972-981. PubMed ID: 26296158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UDP-glucuronosyltransferase (UGT) 1A9-overexpressing HeLa cells is an appropriate tool to delineate the kinetic interplay between breast cancer resistance protein (BRCP) and UGT and to rapidly identify the glucuronide substrates of BCRP.
    Jiang W; Xu B; Wu B; Yu R; Hu M
    Drug Metab Dispos; 2012 Feb; 40(2):336-45. PubMed ID: 22071170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment and modulation of forsythiaside absorption with MDCKII cells and validation with in situ intestinal experiment.
    Li YX; Zhang RQ; Peng C
    Eur J Drug Metab Pharmacokinet; 2012 Sep; 37(3):179-86. PubMed ID: 22430364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.